Overview Dividends

(PFE) Pfizer - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7170811035

Vaccines, Antivirals, Oncology, Immunology, Sterile-Injectables

PFE EPS (Earnings per Share)

EPS Growth (3Y CAGR): -25.92%
EPS Trend (3Y Correlation): -21.7%

PFE Revenue

Revenue Growth (3Y CAGR): -14.63%
Revenue Trend (3Y Correlation): -50.9%

Description: PFE Pfizer September 25, 2025

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells a broad portfolio of biopharmaceutical products worldwide, spanning small-molecule drugs, biologics, vaccines, and biosimilars across multiple therapeutic areas.

Key therapeutic segments include cardiovascular and migraine treatments (e.g., Eliquis, Nurtec ODT), infectious-disease vaccines (Prevnar, Abrysvo), COVID-19 prevention and therapy (Comirnaty, Paxlovid), and specialty medicines for chronic immune, inflammatory, hematologic, and endocrine disorders (Xeljanz, Enbrel, Oxbryta, Ibrance, etc.). The company also operates a contract-manufacturing business and serves a diverse customer base that includes wholesalers, hospitals, pharmacies, and government agencies.

Recent performance metrics (as of Q2 2024) show a revenue run-rate of roughly $14 billion, driven largely by sustained demand for COVID-19 products and a 7 % YoY growth in the vaccine segment, while the biosimilar portfolio contributed a 12 % increase in margin expansion. A primary sector driver is the aging global population, which underpins rising demand for chronic-disease therapies, and a secondary driver is the ongoing shift toward mRNA and antiviral platforms, where Pfizer’s partnership with BioNTech positions it to capture a growing market share.

For a deeper, data-rich analysis of Pfizer’s valuation dynamics and scenario modeling, you may find additional insights on ValueRay helpful.

PFE Stock Overview

Market Cap in USD	138,102m
Sub-Industry	Pharmaceuticals
IPO / Inception	2012-08-13

PFE Stock Ratings

Growth Rating	-41.3%
Fundamental	61.2%
Dividend Rating	78.3%
Return 12m vs S&P 500	-21.9%
Analyst Rating	3.56 of 5

PFE Dividends

Dividend Yield 12m	8.81%
Yield on Cost 5y	7.77%
Annual Growth 5y	3.89%
Payout Consistency	97.8%
Payout Ratio	73.8%

PFE Growth Ratios

Growth Correlation 3m	-18.2%
Growth Correlation 12m	-16.3%
Growth Correlation 5y	-71.5%
CAGR 5y	-15.80%
CAGR/Max DD 3y (Calmar Ratio)	-0.29
CAGR/Mean DD 3y (Pain Ratio)	-0.41
Sharpe Ratio 12m	-0.16
Alpha	-19.75
Beta	0.465
Volatility	20.78%
Current Volume	157635.8k
Average Volume 20d	47729.8k
Stop Loss	23.5 (-3.3%)
Signal	-1.03

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (10.75b TTM) > 0 and > 6% of Revenue (6% = 3.83b TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 3.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 9.36% (prev -10.66%; Δ 20.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 15.19b > Net Income 10.75b (YES >=105%, WARN >=100%)

Net Debt (60.16b) to EBITDA (22.77b) ratio: 2.64 <= 3.0 (WARN <= 3.5)

Current Ratio 1.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (5.71b) change vs 12m ago 0.18% (target <= -2.0% for YES)

Gross Margin 67.34% (prev 49.11%; Δ 18.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 30.23% (prev 26.01%; Δ 4.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.65 (EBITDA TTM 22.77b / Interest Expense TTM 2.83b) >= 6 (WARN >= 3)

Altman Z'' 3.54

(A) 0.03 = (Total Current Assets 43.70b - Total Current Liabilities 37.73b) / Total Assets 206.09b

(B) 0.57 = Retained Earnings (Balance) 117.61b / Total Assets 206.09b

(D) 0.94 = Book Value of Equity 109.65b / Total Liabilities 117.08b

Total Rating: 3.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 61.24

1. Piotroski 5.50pt = 0.50

2. FCF Yield 6.66% = 3.33

3. FCF Margin 19.49% = 4.87

4. Debt/Equity 0.70 = 2.26

5. Debt/Ebitda 2.64 = -1.21

6. ROIC - WACC (= 4.31)% = 5.39

7. RoE 11.96% = 1.00

8. Rev. Trend -50.93% = -3.82

9. EPS Trend -21.68% = -1.08

What is the price of PFE shares?

As of November 05, 2025, the stock is trading at USD 24.30 with a total of 157,635,782 shares traded.
Over the past week, the price has changed by -0.82%, over one month by -8.06%, over three months by +3.27% and over the past year by -6.32%.

Is Pfizer a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Pfizer is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 61.24 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PFE is around 22.35 USD . This means that PFE is currently overvalued and has a potential downside of -8.02%.

Is PFE a buy, sell or hold?

Pfizer has received a consensus analysts rating of 3.56. Therefor, it is recommend to hold PFE.

Strong Buy: 7
Buy: 2
Hold: 15
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the PFE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	28.8	18.6%
Analysts Target Price	28.8	18.6%
ValueRay Target Price	24.3	-0%

PFE Fundamental Data Overview November 01, 2025

Market Cap USD = 138.10b (138.10b USD * 1.0 USD.USD)
P/E Trailing = 12.8519
P/E Forward = 8.673
P/S = 2.1635
P/B = 1.7359
P/EG = 3.7725
Beta = 0.465
Revenue TTM = 63.83b USD
EBIT TTM = 15.99b USD
EBITDA TTM = 22.77b USD
Long Term Debt = 56.63b USD (from longTermDebt, last quarter)
Short Term Debt = 4.29b USD (from shortTermDebt, last quarter)
Debt = 61.80b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.16b USD (from netDebt column, last quarter)
Enterprise Value = 186.65b USD (138.10b + Debt 61.80b - CCE 13.25b)
Interest Coverage Ratio = 5.65 (Ebit TTM 15.99b / Interest Expense TTM 2.83b)
FCF Yield = 6.66% (FCF TTM 12.44b / Enterprise Value 186.65b)
FCF Margin = 19.49% (FCF TTM 12.44b / Revenue TTM 63.83b)
Net Margin = 16.85% (Net Income TTM 10.75b / Revenue TTM 63.83b)
Gross Margin = 67.34% ((Revenue TTM 63.83b - Cost of Revenue TTM 20.85b) / Revenue TTM)
Gross Margin QoQ = 64.29% (prev 71.65%)
Tobins Q-Ratio = 0.91 (Enterprise Value 186.65b / Total Assets 206.09b)
Interest Expense / Debt = 1.06% (Interest Expense 654.0m / Debt 61.80b)
Taxrate = 4.63% (141.0m / 3.04b)
NOPAT = 15.25b (EBIT 15.99b * (1 - 4.63%))
Current Ratio = 1.16 (Total Current Assets 43.70b / Total Current Liabilities 37.73b)
Debt / Equity = 0.70 (Debt 61.80b / totalStockholderEquity, last quarter 88.69b)
Debt / EBITDA = 2.64 (Net Debt 60.16b / EBITDA 22.77b)
Debt / FCF = 4.84 (Net Debt 60.16b / FCF TTM 12.44b)
Total Stockholder Equity = 89.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.22% (Net Income 10.75b / Total Assets 206.09b)
RoE = 11.96% (Net Income TTM 10.75b / Total Stockholder Equity 89.88b)
RoCE = 10.91% (EBIT 15.99b / Capital Employed (Equity 89.88b + L.T.Debt 56.63b))
RoIC = 9.96% (NOPAT 15.25b / Invested Capital 153.00b)
WACC = 5.65% (E(138.10b)/V(199.90b) * Re(7.73%) + D(61.80b)/V(199.90b) * Rd(1.06%) * (1-Tc(0.05)))
Discount Rate = 7.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.52%
[DCF Debug] Terminal Value 73.62% ; FCFE base≈9.39b ; Y1≈7.15b ; Y5≈4.40b
Fair Price DCF = 14.55 (DCF Value 82.72b / Shares Outstanding 5.69b; 5y FCF grow -28.32% → 3.0% )
EPS Correlation: -21.68 | EPS CAGR: -25.92% | SUE: 1.83 | # QB: 8
Revenue Correlation: -50.93 | Revenue CAGR: -14.63% | SUE: 0.57 | # QB: 0

Additional Sources for PFE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle